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REPORT
Normal Levels of Wild-Type Mitochondrial DNA Maintain
Cytochrome c Oxidase Activity for Two Pathogenic Mitochondrial
DNA Mutations but Not for m.3243ArG
Steve E. Durham, David C. Samuels, Lynsey M. Cree, and Patrick F. Chinnery
Mitochondrial DNA (mtDNA) mutations are a common cause of human disease and accumulate as part of normal ageing
and in common neurodegenerative disorders. Cells express a biochemical defect only when the proportion of mutated
mtDNA exceeds a critical threshold, but it is not clear whether the actual cause of this defect is a loss of wild-type mtDNA,
an excess of mutated mtDNA, or a combination of the two. Here, we show that segments of human skeletal muscle
fibers harboring two pathogenic mtDNA mutations retain normal cytochrome c oxidase (COX) activity by maintaining
a minimum amount of wild-type mtDNA. For these mutations, direct measurements of mutated and wild-type mtDNA
molecules within the same skeletal muscle fiber are consistent with the “maintenance of wild type” hypothesis, which
predicts that there is nonselective proliferation of mutated and wild-type mtDNA in response to the molecular defect.
However, for the m.3243ArG mutation, a superabundance of wild-type mtDNA was found in many muscle-fiber sections
with negligible COX activity, indicating that the pathogenic mechanism for this particular mutation involves interference
with the function of the wild-type mtDNA or wild-type gene products.
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Pathogenic mtDNA mutations affect the quality or quan-
tity of respiratory-chain proteins.1,2 Point mutations af-
fecting tRNA genes and large deletions that remove mul-
tiple tRNA genes lead to a global decrease in mitochondrial
protein synthesis and defects affecting a number of dif-
ferent respiratory chain complexes, which often involve
complex IV (cytochrome c oxidase [COX]). Most patients
with multisystem mtDNA disease harbor a mixture of mu-
tated and wild-type mtDNA (heteroplasmy). Single-cell3,4
and transmitochondrial cybrid5–8 studies have shown that
the proportion of mutated mtDNA exceeds a critical
threshold in cells expressing a biochemical defect. The
precise threshold differs from mutation to mutation and
also between cell types. For some mtDNA mutations, the
threshold appears to be sharp and clearly defined,3 but,
for others, the transition is gradual.9 Understanding the
threshold effect is the key to understanding the mito-
chondrial defect at the cellular level that underpins organ
dysfunction and human disease.
The threshold could be the result of the functional com-
plementation of mutated mtDNA by excess wild-type ge-
nomes,10 possibly through increased rates of transcrip-
tion.8,11 However, there is emerging evidence that the
amount of mtDNA within cells is carefully regulated, and
most, if not all, mtDNA molecules are required to main-
tain optimal mitochondrial function, including mtDNA
transcription and translation.12,13 In keeping with this,
compensatory mitochondrial proliferation in response to
“sick mitochondria”14 can occur in the absence of an overt
biochemical defect, forming COX-positive ragged-red
skeletal muscle fibers.3,4
Adjacent cells within the same organ often contain dif-
ferent proportions of mutated and wild-type mtDNA,3,4,15,16
limiting the value of data collected from tissue homoge-
nates. To provide a definitive understanding of the thresh-
old effect, the absolute amount of wild-type and mutated
mtDNA must be studied at the cellular level. Skeletal mus-
cle is ideal for this purpose, because different segments of
the same multinucleate giant cell can have normal or ab-
normal COX activity.17 Our preliminary data revealed con-
siderable variation in the amount of mtDNA between
healthy muscle fibers, at least partly due to differences in
fiber volume. This could obscure a clear relationship be-
tween the biochemical defect and the absolute amount of
mutated and wild-type mtDNA. Subsequent work was
therefore performed on serial sections through the same
muscle fiber.
Left-quadricep-muscle biopsies were performed under
local anesthetic, and 3–5-mm3 blocks of fresh skeletal mus-
cle were transversely orientated and were mounted on fil-
ter paper before being snap frozen in supercooled isopen-
tane cooled (to 150C) in liquid nitrogen. The entire
tissue block was sectioned (into 20-mm sections) onto
glass-membrane slides for laser microdissection. Muscle
histochemical analysis was performed on all the sections
from each biopsy by staining for COX and succinate de-
hydrogenase (SDH) sequentially. Entirely synthesized
from nuclear gene transcripts, SDH (complex II) is an ef-
fective counterstain used in the identification of COX-
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Table 1. Amount of mtDNA Measured in Type 1 Skeletal Muscle Fibers
Dissected from 20-mm Cryostat Sections of Control Muscle
Measurement
No. of mtDNA Molecules with Method
Standard Lysis
Buffer
Lysis Buffer
without EDTA
PCR
Buffer
Lysis and
Purification
1 32,200 19,800 761 8,300
2 27,800 13,400 9,430 6,030
3 1,950 11,500 2,420 2,740
4 2,050 15,400 2,990 7,910
5 42,800 12,900 3,630 7,640
6 12,200 10,100 3,200 4,230
7 1,300 13,200 15,800 17,300
8 5,010 12,500 4,210 2,740
9 957 13,300 11,500 16,700
10 42,100 14,800 1,530 40,500
11 8,350 45,200 … 7,520
12 33,800 11,100 … 64,600
Mean 17,543 16,100 5,547 15,518
SD 16,835 9,494 4,966 18,630
NOTE.—Fibers were lysed using different methods. “Standard lysis buffer” was 50 mM Tris-
HCl (pH 8.5), with 1 mM EDTA (pH 8), 0.5% Tween 20, and 100 mg Proteinase K. “Lysis buffer
without EDTA” was 50 mM Tris-HCl (pH 8.5), 0.5% Tween 20, and 100 mg Proteinase K. “PCR
buffer” was ABI GeneAmp PCR Buffer (1#), 0.5% Tween 20, and 100 mg Proteinase K. “Lysis
and purification” was the same as for standard lysis buffer, followed by column purification
(Montage PCR filter units [Millipore]) in accordance with the manufacturer’s instructions. Lysis
was performed at 55C for 2 h, followed by heat inactivation at 95C for 10 min before immediate
real-time PCR to measure mtDNA copy number (see text). The inclusion of EDTA in the buffer
increases the variability, whereas a post-lysis purification markedly decreases the copy number
measurement. Lysis buffer without EDTA was used for subsequent experiments. Each value in
the table was obtained from a different muscle fiber section.
Table 2. Effect of Lysis Temperature and Lysis Incubation
Time on mtDNA Copy Number in Control Muscle
No. of mtDNA Molecules with
2-h Incubation at 16-h Incubation at
Measurement 37C 55C 37C 55C
1 15,200 18,500 17,800 23,000
2 7,640 19,500 20,700 20,400
3 22,100 16,300 12,400 18,000
4 15,400 15,400 17,100 37,200
5 20,700 16,800 27,200 29,800
6 15,400 24,400 15,900 19,500
7 21,400 19,800 51,200 22,400
8 15,300 15,400 19,800 24,300
9 15,600 14,900 23,200 25,100
10 15,600 22,200 22,500 27,900
11 17,800 16,900 14,900 26,000
12 16,600 18,500 21,600 31,300
Mean 16,562 18,217 22,025 25,408
SD 3,818 2,903 10,043 5,483
NOTE.—Measurements from control skeletal muscle fibers were taken
from 20-mm cryostat sections, by use of lysis buffer without EDTA and
real-time PCR to measure total mtDNA (see text) in control muscle type
1 fibers. Consistently higher values were obtained by incubation at 55C
for 16 h. Each value in the table was obtained from a different muscle
fiber section.
deficient muscle fibers. The sections were digitally pho-
tographed. Each fiber was given a numerical code and was
followed up for the entire depth of the biopsy (42–49 sec-
tions). Each muscle-fiber section was classified as COX
positive (i.e., showed brown staining), COX negative (i.e.,
showed the blue SDH counterstaining), or intermediate,
as described elsewhere.18 Specific fibers were chosen for
further analysis on the basis of the following criteria: (1)
the same fiber showed a clear transition from COX posi-
tive to COX negative, and (2) the cross-sectional area of
the fiber remained constant. Individual fibers were pho-
tographed, were laser captured (Leica LMD), and were sub-
jected to cell lysis and DNA extraction.
Before investigating the patients with mtDNA muta-
tions, we studied the effect of different lysis techniques
and enzyme histochemistry on the amount of mtDNA
within single muscle fibers from healthy control subjects.
Serial sections from the same control muscle fiber were
stained for COX in isolation, were stained sequentially
with COX and SDH, and were left unstained. Individual
fiber sections were laser captured and were lysed using
different techniques (tables 1 and 2). We observed no ef-
fect on the quality of the data obtained from any of the
combinations of histochemical assays. The most consis-
tent and greatest amount of mtDNA was obtained from
cells lysed for 16 h in 50 mM Tris-HCl (pH 8.5), with 0.5%
Tween 20 and 100 mg Proteinase K at 55C, followed by
heat inactivation at 95C for 10 min. Similar experiments
showed that a more reliable estimate of cellular mtDNA
content was obtained by splitting the lysate into 2-ml frac-
tions and taking a minimum of four measurements, rather
than a single measurement from 20 ml (data not shown).
Each muscle-fiber section was lysed in 20 ml, which was
split into two aliquots: 10 ml for real-time PCR quantifi-
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Figure 1. Relationship between wild-type and mutated mtDNA and COX deficiency for three pathogenic mtDNA mutations. a, 4.9-kb
mtDNA deletion. b, m.10010TrC MTTG point mutation. c, m.3243ArG MTTL1 point mutation. Serial 20-mm sections through the same
left-quadricep skeletal muscle fiber show the absolute amount of mutated mtDNA (red bars), the absolute amount of wild-type mtDNA
(green bars), and the percentage of mutated mtDNA (blackened squares). Adjacent sections are linked by a solid line, and nonadjacent
sections are linked by a dashed line. Error bars correspond to the SEM for the three measurements made on each tissue section. A
photomicrograph of the corresponding muscle-fiber section before lysis is shown below, stained histochemically for COX activity (brown)
and SDH activity (blue). Strong brown staining indicates normal COX activity (Positive), whereas strong blue staining indicates COX
deficiency (Negative). Brown-blue staining indicates an intermediate level of COX activity (Transition), corresponding to the transition
region between normal and abnormal COX activity. Individual fibers were stained, photographed, captured by laser microdissection, and
lysed before molecular genetic analysis (see text).
Figure 2. Relationship between wild-type and mutated mtDNA
and COX deficiency for three pathogenic mtDNA mutations. The
legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
cation (4# 2-ml replicates) of the total amount of mtDNA
within each fiber section (mtDNA copy number) and 10
ml for quantifying heteroplasmy. mtDNA copy number
was measured by real-time PCR by use of iQ Sybr Green
on the BioRad ICycler (BioRad) with a target template
spanning from nt 3459 to nt 3568 of MTND1 (MIM
516000) (with forward primer 5′-ACGCCATAAAACTCTT-
CACCAAAG-3′ and reverse primer 5′-GGGTTCATAGTAG-
AAGAGCGATGG-3′). Absolute quantification was per-
formed by the standard-curve method by use of a purified
PCR product quantified by UV absorbance at 260 nm, with
each measurement made in quadruplicate, as described
elsewhere.18
For the 4.9-kb deletion, the proportion of mutated
mtDNA was determined by real-time PCR (with forward
primer 5′-ACCTTGGCTATCATCACCCGAT-3′ and reverse
primer 5′-AGTGCGATGAGTAGGGGAAGG-3′) by use of iQ
Sybr Green on the BioRad ICycler (BioRad) with a target
template spanning from nt 11144 to nt 11250 of MTND4
(MIM 516003), which was deleted in the patient.19 Each
assay was performed in quadruplicate. The proportion of
mutated mtDNA was then calculated from the data for
MTND4 (wild-type molecules) and MTND1 (total mtDNA).
For the mtDNA point mutations, the proportion of mu-
tated mtDNA was determined by last-cycle fluorescent
PCR with use of a labeled primer to generate mutated and
wild-type fragments, which were sized on a fluorescent
analyzer (Beckman Coulter CEQ 8000) as described else-
where20,21 (by an RFLP-based method for m.3243ArG and
m.10010TrC), enabling a direct calculation of the amount
of mutated and wild-type mtDNA within each fiber.
A total of 400 muscle fibers were examined through 49
serial 20-mM sections from a patient harboring the 4.9-kb
“common deletion” of mtDNA (for patient details, see ap-
pendix A). COX-SDH histochemistry was used to identify
seven transitions from regions of normal COX activity
(COX-positive regions) to regions of COX deficiency
(COX-negative regions) ( fiber sections) (fig. 1a).np 41
COX-negative sections contained more mtDNA molecules
than did the COX-positive sections (fig. 1a) (mean in-
crease 2.94-fold, ; paired t test ) andSDp 1.50 Pp .004
had a higher percentage of mutated mtDNA (96.02% vs.
55.15%; ; ), consistent with5SDp 24.97 Pp 7.17# 10
published data,15,16 and a lower percentage of wild-type
mtDNA (mean decrease 5.15-fold, ; ).SDp 5.10 P ! .001
Between these regions, fiber sections contained interme-
diate values, demonstrating the gradual transition from
COX-positive to COX-negative sections (fig. 1a and fig.
2a).
Plotting the data from all 41 segments on one graph
revealed a clear relationship between COX activity and
the amount of wild-type mtDNA (fig. 3a). COX-positive
sections contained a varied amount of mutated mtDNA,
but the number of wild-type molecules was relatively con-
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Figure 3. Relationship between the amount of wild-type mtDNA
and the percentage of mutated mtDNA. The amount of wild-type
mtDNA is shown relative to an estimation of the optimal amount
of wild-type mtDNA based on the average amount of wild-type
mtDNA in adjacent COX-positive regions from the same muscle
fiber. Each data point represents measurements made on a single
muscle-fiber segment. Error bars correspond to the SEM for three
independent assays. a, 4.9-kb mtDNA deletion ( ). b,np 41
m.10010TrC MTTG point mutation ( ). c, m.3243ArG MTTL1np 37
point mutation ( ). The histochemical phenotype is colornp 33
coded: red circles indicate COX-positive regions, blue triangles
indicate COX-negative regions, and gray squares indicate transition
regions. The superimposed curve describes predictions made by
the in silico model of mtDNA replication and heteroplasmy in non-
dividing cells that is based on the “maintenance of wild type”
hypothesis (see text and appendix B). The model results are cal-
culated using equation (1) with . This value is derived fromap 16
independent experimental data measuring the maximum amount
of mitochondrial proliferation seen in skeletal muscle harboring
pathogenic mtDNA mutations. (See work by Chinnery and Samuels22
and Capps et al.23 for a detailed explanation with citations of the
original data that underpin the model.)
stant ( ). By contrast, high percentage levels ofSDp 0.15
mutated mtDNA were associated with a dramatic reduc-
tion in wild-type levels and COX deficiency. These obser-
vations correspond with predictions made by an in silico
model based on the “maintenance of wild type” hypoth-
esis, which assumes that healthy fiber segments contain
an optimal amount of mtDNA required to maintain COX
activity22 (for an overview of the modeling methods, see
appendix B). When the mtDNA are mutated and com-
promise expression of the 13 mtDNA-encoded proteins, a
segment of the multinucleated cell responds by nonselec-
tively proliferating its entire mtDNA content, to restore
wild-type mtDNA to its optimal level. This mechanism
will maintain wild-type mtDNA at near-optimal levels, but
only up to a specific point. Beyond this point, further
proliferation leads to the loss of wild-type genomes at the
expense of mutated genomes, which are in excess, with
the consequent loss of COX activity.22
To determine whether this effect was specific to the 4.9-
kb “common deletion,” we performed similar analysis
on six transitions from COX-positive to COX-negative
regions ( fiber sections) (figs. 1b and 2b) for annp 37
mtDNA tRNA gene point mutation also known to glob-
ally impair intramitochondrial protein synthesis:
m.10010TrC MTTG21 (MIM 590035) (for patient details,
see appendix A). As with the 4.9-kb deletion, the COX-
negative fiber sections contained a greater number of
mtDNA molecules (mean increase 4.77-fold, ;SDp 2.23
), a greater percentage of mutated mtDNA (98.56%Pp .037
vs. 91.67%, ; ), and a lower6SDp 3.69 Pp 4.45# 10
number of wild-type mtDNA (mean decrease 1.76-fold,
; ) than did the COX-positive sections,SDp 1.10 Pp .203
although the last observation did not reach statistical sig-
nificance. There was a similar relationship between the
amount of wild-type mtDNA and the percentage level of
mutated mtDNA (fig. 3b).
Here, we provide the first direct evidence supporting the
in silico model.22 This accurately describes events in single
muscle-fiber segments in vivo and provides an alternative
explanation for previously published data. Proliferation of
the entire mtDNA pool in response to a decrease in the
amount of wild-type mtDNA gives the impression of the
preferential replication of mutated molecules, when the
signal to increase replication is not selective. The thresh-
old effect is a direct consequence of this process, rather
than being the result of the loss of reserve capacity, and
is due to an inability to maintain wild-type mtDNA at an
optimal level.
The m.3243ArG MTTL1 (MIM 590050) point mutation
has distinct histopathological features, including COX-
positive ragged-red fibers. Since it is the most common
inherited heteroplasmic mtDNA mutation, we also studied
eight transitions in five muscle fibers from a patient with
this mutation ( fiber sections) (figs. 1c and 2c) (fornp 33
patient details, see appendix A). As expected, COX-neg-
ative fiber sections contained a greater number of mtDNA
molecules (mean increase 9.95-fold, ; )SDp 4.99 Pp .006
and a higher percentage of mutated mtDNA (91.35% vs.
58.55%, ; ) than did the COX-4SDp 22.15 Pp 2.23# 10
positive sections. Again, each COX-positive segment con-
tained a similar amount of wild-type mtDNA, despite each
segment containing different percentage levels of mutated
mtDNA (fig. 3c). However, unlike for the other mutations,
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regions of intermediate COX activity contained the same
amount of wild-type mtDNA as did the COX-positive
regions, with the amount of wild-type mtDNA up to six-
fold greater in COX-negative segments (mean increase
5.86-fold, ; ). In other words, supra-SDp 1.84 Pp .013
normal levels of wild-type mtDNA could not maintain
COX-activity, raising the possibility that the m.3243ArG
MTTL1 mutation suppresses the normal function of the
wild-type tRNALeu(UUR) in human skeletal muscle fibers.
All three of these mtDNA mutations impair intramito-
chondrial protein synthesis, but there is a poor correlation
between the translational and biochemical defects for
m.3243ArG,24,25 indicating an additional pathogenic
mechanism other than decreased steady-state levels of
aminoacylated tRNA.26 A primary defect in 5-taurinome-
thyluridine modification of the first (wobble) position of
the anticodon leads to impaired UUG decoding in
m.3243ArG and to a qualitative defect in translation.26,27
Although similar defects were observed with other tRNA
mutations,26 they are not a universal finding,26 indicating
a fundamental difference in disease mechanism between
different tRNA mutations that may correlate with the clin-
ical phenotype.27
How could a mutated tRNA interfere with the function
of wild-type mtDNA molecules? Specific MTTL1 muta-
tions have been shown to disrupt the aminoacylation of
wild-type tRNA, although this does not appear to be the
case for m.3243ArG.28 Alternatively, since m.3243ArG is
located within the binding site of the mitochondrial tran-
scription termination factor, this could lead to reduced
transcription termination at the 16S/tRNALeu(UUR) bound-
ary, and the high levels of steady-state 16S transcripts ob-
served in myoblasts.29 Associated high levels of the 19S
RNA in m.3243ArG cybrids (an RNA intermediate incor-
porating the 16S RNA, tRNALeu(UUR), and ND1 transcripts)
incorporated into mitochondrial polyribosomes could
lead to ribosomal stalling.30 mtDNA proliferation and in-
creased rates of transcription would exacerbate this effect,
generating a positive-feedback mechanism and further in-
hibition of ribosomal function. In some ways, this is sim-
ilar to the “dominant negative effect” seen in some Men-
delian traits. However, this term must be used with
caution, and comparing mitochondrial and Mendelian ge-
netics is not straightforward. For example, mtDNA dele-
tions have been described as having both “dominant”31
and “recessive”32 properties, on the basis of measurement
of different aspects of the associated molecular biology.
Analysis of the tRNA levels in each segment could help
to resolve this complex issue for specific mtDNA muta-
tions, including m.3243ArG.
It is intriguing that we consistently observed a decrease
in the total amount of mtDNA in leukocytes from patients
with the m.3243ArG MTTL1 mutation.20 Unlike skeletal
muscle, which is postmitotic, the leukocyte population is
continuously recycled in the peripheral circulation. The
low levels of mtDNA seen in m.3243ArG leukocytes may
reflect this fundamental difference between postmitotic
and dividing cells, although other mechanisms have been
proposed involving mitochondrial fragility.33
Our current model does not account for the structural
organization of mitochondria and mtDNA within skeletal
muscle fibers but assumes that the mtDNA molecules are
freely mixing.22 Some degree of compartmentalization
clearly must occur to produce defined segments of COX
deficiency,17 but the correspondence between observed
values measured in skeletal muscle and the predictions
made by the model indicate that this is less important
over short distances (such as the 20-mm section thickness
studied here). Incorporating some form of compartmen-
talization is likely to be important for studying the long-
term spread of a COX-deficient segment along the muscle
fiber length.
These observations add to the growing body of evidence
against the concept of a surplus of mitochondrial genomes
within healthy human cells and favor the close correlation
between transcription rates and mtDNA copy number.
This supports the development of treatment strategies
aimed at increasing the amount of mtDNA in patients
with mtDNA disease. A similar approach would also pre-
vent somatic mtDNA mutations that contribute to aging
and neurodegeneration. However, this might not be ap-
propriate for every mtDNA defect, because some may lead
to high levels of mtDNA proliferation, which correlates
with apoptosis.34 For these mutations, new therapeutic
strategies should be aimed at increasing specifically the
amount of wild-type mtDNA, not at increasing the total
amount of mtDNA.
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Appendix A
Clinical Details of the Patients with mtDNA Myopathy
Patient 1 is a 37-year-old man with chronic progressive
external ophthalmoplegia who presented in his 20s with
bilateral ptosis and ophthalmoplegia and who later de-
veloped a mild proximal myopathy and dysphagia. His
serum creatine kinase was 215 IU/liter (normal !170 IU/
liter), his fasting blood lactate was 1.1 mM/liter, and his
fasting cerebrospinal fluid lactate was 1.6 mM/liter. A left-
quadricep-muscle biopsy, which was described in detail
elsewhere,17 revealed 15% ragged-red skeletal muscle fibers
and 20% COX-negative fibers. A Southern blot showed
that 20% of the muscle mtDNA had the 4.9-kb “common”
mtDNA deletion.
Patient 2 is a 43-year-old woman with short stature who
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was described elsewhere21 and who presented with an en-
cephalopathy at age 20 years. She went on to develop
cognitive impairment, bilateral optic atrophy, sensorineu-
ral deafness, ataxia, dystonia, and a spastic paraparesis.
She had glucose intolerance. Her serum creatine kinase
ranged between normal and 1,800 IU/liter (normal !170
IU/liter), and her serum lactate was 5.3 mM/liter. Her di-
agnostic muscle biopsy revealed 30% ragged-red fibers
and 21% COX-negative fibers. Complete sequencing of
muscle mtDNA revealed two heteroplasmic substitutions:
m.10010TrC MTTG, thought to be the primary patho-
genic mutation in this case, and the m.5656ArG non-
coding substitution, which has been described in a large
number of healthy control subjects (mtDB Web site).21
Patient 3 is a 30-year-old woman with longstanding bi-
lateral sensorineural deafness and short stature, who pre-
sented at age 30 years with recurrent seizures and an en-
cephalopathy. She later developed migraine, diabetes,
recurrent vomiting, gastrointestinal pseudo-obstruction,
cardiac failure, optic atrophy, and a proximal myopathy.
Her serum creatine kinase was 302 IU/liter (normal !170
IU/liter), and her fasting blood lactate ranged from 3.3
to 5.5 mM/liter. A left-quadricep-muscle biopsy revealed
30% ragged-red fibers and 2% COX-negative fibers. The
m.3243ArG MTTL1 mutation was detected in blood (49%
mutated mtDNA) and muscle (52% mutated mtDNA).
Appendix B
In Silico Modeling
Our simulation and mathematical model of mtDNA rep-
lication is explained elsewhere.22,23 For loss-of-function
mutations (where the total amount of wild-type mtDNA
is the primary determinant of mitochondrial function),
this model predicts that the wild-type copy number W in
a cell will be a simple function of the mutation level m,
given by
W 1m
p , (1)
a1Noptimal 1 m( )a
where Noptimal is the number of mtDNA molecules in a
normal cell with no mutant mtDNA and a is a parameter
defining the maximum proliferation in the cell.
Web Resources
The URLs for data presented herein are as follows:
mtDB, http://www.genpat.uu.se/mtDB/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MTND1, MTND4, MTTG, and
MTTL1)
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